Therefore, it is anticipated that an orally absorbable PTP1B inhibitor would demonstrate anti-obesity effects by enhancing leptin sensitivity in obese subjects. The gene discussed is PTPN1; the disease is obesity due to melanocortin 4 receptor deficiency.